Navigation Links
COPD A Little Known Killer Disease

According to a survey conducted by a charity organization it was shocking to find that about three-quarters of the people in UK are ignorant about the existence// of chronic obstructive pulmonary disease (COPD).

The general public said that they have never heard of the disease. COPD is UK’s fifth-biggest killer disease as it affects 3 million people in the UK and causes around 30,000 deaths a year. The medical charity organization called the Developing Patient Partnerships said that about 72% of people were unaware of the disease.

COPD kills more number of people those suffering from breast, prostate or bowel cancer. COPD is caused by smoking, other causes include chronic bronchitis and emphysema. Mostly people think that COPD is a minor disease and can be cured easily. Hence Developing Patient Partnerships has planned to create awareness about the disease by launching a campaign called Ever Smoked? The main aim of this campaign is to raise awareness of the disease and its symptoms and encourage people to quit smoking.


'"/>




Page: 1

Related medicine news :

1. Little sleep as bad as no sleep
2. Aspirin Induced Asthma , A Little-Known Inducer
3. A Little Weight Loss Found To Make A Significant Difference In Men
4. Little Known DNA Repair Enzyme May Be A Tumor Suppressor Gene
5. Little Clinic LLC Plans Super Medical Clinics in Publix Super Markets
6. Trendsetters: Little girls fast track into ladies even before they know it
7. The Little Known Facts of Junk DNA
8. Too Much Or Little Sleep Increases Risk Of Diabetes
9. Diabetes Risk Pronounced With Too Much or Too Little Sleep
10. Reverse Heart Transplant Surgery On A Little Girl Makes History
11. Most People With Arthritis Do Little Or No Exercise At All
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: COPD Little Known Killer Disease

Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6New Robotic Arm Has Softer Surgical Touch 55753 1New Robotic Arm Has Softer Surgical Touch 55753 2Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 1Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 2Nielsen Announces Final Entry Deadline Extension of September 10th for the First Ever CLIO Healthcare Awards 55750 3Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 1Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 2Cardio3 BioSciences Presents Update on C Cure 28R 29 Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress 13742 3
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2